Questions About Cancer? 1-800-4-CANCER

Lymphoma - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Dose-adjusted Chemotherapy for Untreated c-MYC-positive Lymphomas
    (Posted: 01/25/2011) - In this trial, adult patients with newly diagnosed Burkitt lymphoma or c-MYC-positive diffuse large B-cell lymphoma will be separated into low-risk and high-risk groups; those in the low-risk group will be treated with at least three cycles of dose-adjusted EPOCH-R chemotherapy, while high-risk patients will receive six cycles.
  • Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers
    (Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
  • Targeted Therapy for Mantle Cell Lymphoma
    (Posted: 01/10/2006) - In this trial, researchers will treat mantle cell lymphoma patients with a drug called bortezomib, followed by induction therapy with bortezomib and a chemotherapy combination known as DA-EPOCH-R, along with the drug filgrastim to stimulate white blood cell production. Half of the patients will subsequently receive bortezomib maintenance therapy.
  • Preventing Graft-versus-Host Disease during Hematologic Cancer Treatment
    (Posted: 05/31/2005) - Researchers are investigating whether an immunosuppressive drug, sirolimus, can work with cyclosporine to prevent graft-versus-host disease (GVHD) more effectively than cyclosporine alone following allogeneic hematopoietic stem cell transplantation.